Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Stephen Lessnick
Research Inst Nationwide Children's Hosp, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Salarius Pharmaceuticals, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Lessnick owns an equitable interest in Salarius. Salarius has the licensing rights to a compound, "Inhibiters of Enzyme LSD1." Dr. Lessnick is not the inventor. Dr. Lessnick is utilizing the compound in his R01 funded research, for Aim 2. The compound is not utilized for Aim 1 or Aim 3. Dr. Lessnick is not testing the efficacy, quality or safety of the compound as part of this research. The Institution determined that Dr. Lessnick has a significant financial interest in Salarius that may create an appearance of a conflict of interest, but there was not a concern that the financial interest could necessarily affect the objectivity in the design/reporting/outcome of the research.
(PQB-2) "Driver" vs. "passenger" epigenetic events in Ewing sarcoma
Our current ability to discriminate between 'driver' and 'passenger' epigenetic events is rudimentary at best, primarily because the mechanisms by which epigenetic regulators get targeted to critical genomic loci is poorly understood. Our groups have focused on the EWS/FLI fusion transcription factor driver oncoprotein in Ewing sarcoma as a model to understand the link between the epigenetic machinery and oncogenic transformation. Here we propose to test our hypothesis that EWS/FLI mediates oncogenic transformation by actively relocalizing the histone demethylase LSD1 (and associated epigenetic complexes) to target genes critical for the development of Ewing sarcoma and in doing so to act 'instructively' to induce driver epigenetic modifications.
Filed on May 13, 2016.
Tell us what you know about Stephen Lessnick's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.